THE Therapeutic Goods
Administration is quelling fears
over shortages of morphine, issuing
a statement that it has secured an
alternative to Hospira’s 10mg/1mL
injections.
The furor started when the
company advised the TGA that an
upgrade problem at it’s European
manufacturing plant was set to
cause shortages of the it’s morphine
10mg/1mL injections.
The company also told the TGA
that it expects the shortages would
last up to the first half of 2013.
To offset this issue the TGA
worked Hospira, and has now
confirmed that it has secured an
alternative supply of the injectable
morphine from another source.
“We are confident that there will
be no shortage of morphine 10mg/
1ml injections in Australia,” the TGA
said in a statement.The above article was sent to subscribers in Pharmacy Daily's issue from 19 Dec 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Dec 12
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.